Content about Biopharmaceutical

March 6, 2014

McKesson on Wednesday announced that its board of directors has elected Anthony Coles as a new independent director, effective April 29, 2014.

SAN FRANCISCO — McKesson on Wednesday announced that its board of directors has elected Anthony Coles as a new independent director, effective April 29, 2014. In connection with Coles’ election, the size of the board of directors was increased from nine to 10 members, nine of whom are independent.

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

DUBLIN — Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals.

February 12, 2014

America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday.

WASHINGTON — America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday. These medicines in development — all either in clinical trials or under review by the Food and Drug Administration — include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions.

August 8, 2013

Keryx Biopharmaceuticals announced the submission of a new drug application to the Food and Drug Administration seeking approval for the marketing and sale of Zerenex (ferric citrate coordination complex), the company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease on dialysis.

NEW YORK — Keryx Biopharmaceuticals, Inc., today announced the submission of a new drug application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of Zerenex (ferric citrate coordination complex), the company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease on dialysis.

April 26, 2013

More than 200 drugs for blood cancers are under development, according to a new report by a drug industry trade group.

WASHINGTON — More than 200 drugs for blood cancers are under development, according to a new report by a drug industry trade group.

The Pharmaceutical Research and Manufacturers of America said 241 medicines were in clinical development or under review by the Food and Drug Administration, including 98 for lymphoma, 97 for leukemia, 52 for multiple myeloma and 24 for malignancies of the bone marrow, blood and lymph nodes.

March 11, 2013

Nearly 1,000 biotech drugs and vaccines for more than 100 diseases are currently under development, according to a new report.

WASHINGTON — Nearly 1,000 biotech drugs and vaccines for more than 100 diseases are currently under development, according to a new report.

October 5, 2012

Drug maker Takeda announced that its wholly owned U.S. subsidiary has entered a definitive agreement to acquire LigoCyte Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on developing novel vaccines for gastrointestinal and respiratory indications.

OSAKA, Japan — Drug maker Takeda announced that its wholly owned U.S. subsidiary has entered a definitive agreement to acquire LigoCyte Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on developing novel vaccines for gastrointestinal and respiratory indications.

As part of the deal, Takeda will provide LigoCyte with an upfront payment of $60 million, with future contingent consideration, based on the progress of development projects. LigoCyte's lead product, a vaccine to prevent norovirus gastroenteritis, is in phase-1/2 of clinical development.

September 17, 2012

CVS Caremark has appointed Thomas Moriarty as EVP and general counsel of CVS Caremark.

WOONSOCKET, R.I. — CVS Caremark has appointed Thomas Moriarty as EVP and general counsel of CVS Caremark.

Moriarty most recently served as general counsel at the Celgene, a biopharmaceutical company, where he was responsible for global legal strategy and served on the company's management committee. Prior to that, Moriarty was general counsel and corporate secretary at Medco Health Solutions.

September 4, 2012

Rx Response, an initiative of America’s biopharmaceutical supply system to help ensure the continued flow of medicine to patients in a severe public health emergency, moved to its highest alert status last week as Hurricane Isaac made landfall in Louisiana and across the Gulf Coast.

WASHINGTON — Rx Response, an initiative of America's biopharmaceutical supply system to help ensure the continued flow of medicine to patients in a severe public health emergency, moved to its highest alert status last week as Hurricane Isaac made landfall in Louisiana and across the Gulf Coast.

July 30, 2012

In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.


In July, the country’s largest trade group representing the drug industry released a report showing nearly 200 drugs under clinical development or Food and Drug Administration review for treating mental disorders.


The Pharmaceutical Research and Manufacturers of America released a report listing 187 drugs, including 52 for depression, 37 for schizophrenia and 26 for anxiety disorders.


June 1, 2012

WebMD has tapped Pfizer's group president of animal health, consumer health care and corporate strategy to serve as its new chief executive.

NEW YORK — WebMD has tapped Pfizer's group president of animal health, consumer health care and corporate strategy to serve as its new chief executive.

Cavan Redmond was appointed CEO of WebMD, as well as a member of the company's board of directors on Thursday. He brings to his new role more than 20 years of healthcare experience, encompassing a broad range of global healthcare businesses, including biotechnology, pharmaceuticals, consumer health care and infant nutritionals.

May 9, 2012

The Food and Drug Administration should apply consistent regulatory standards across all biologics, Sandoz plans to state Friday in testimony at an FDA public hearing on draft guidances related to the development of biosimilars.

HOLZKIRCHEN, Germany — The Food and Drug Administration should apply consistent regulatory standards across all biologics, Sandoz plans to state Friday in testimony at an FDA public hearing on draft guidances related to the development of biosimilars.

April 13, 2012

Drug companies invested nearly $50 billion in research and development in 2011, according to a new report by a drug industry trade group.

WASHINGTON — Drug companies invested nearly $50 billion in research and development in 2011, according to a new report by a drug industry trade group.

March 6, 2012

AmerisourceBergen on Tuesday announced that it has signed a definitive agreement to purchase World Courier Group, a privately held global specialty transportation and logistics provider for the biopharmaceutical industry, for $520 million in cash.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday announced that it has signed a definitive agreement to purchase World Courier Group, a privately held global specialty transportation and logistics provider for the biopharmaceutical industry, for $520 million in cash.

September 7, 2011

A specialty biopharmaceutical company has elected two members to its board of directors.

EAST BRUNSWICK, N.J. — A specialty biopharmaceutical company has elected two members to its board of directors.

Savient said that William Owen, current president of the University of Medicine & Dentistry of New Jersey, and David Norton, the former company group chairman of global pharmaceuticals for Johnson & Johnson, were elected Sept. 1.

September 1, 2011

After entering a definitive agreement to acquire biopharmaceutical company Icagen, Pfizer has extended its tender offer for all outstanding shares of common stock.

NEW YORK — After entering a definitive agreement to acquire biopharmaceutical company Icagen, Pfizer has extended its tender offer for all outstanding shares of common stock.

Pfizer, which already has an 11% stake in Icagen, is offering the company a cash transaction of $6 per share. The tender offer, which was extended to Icagen through Pfizer's wholly owned subsidiary Eclipse Acquisition, expires at midnight on Sept. 1.

All other terms and conditions of the tender offer remain unchanged.

August 30, 2011

The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

KNOXVILLE, Tenn. — The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

Provectus Pharmaceuticals said that the company will benefit from Craig Eagle's "vast experience in drug development" as the drug maker seeks to commercialize its cancer and dermatological therapies.

July 28, 2011

Pfizer has entered a definitive agreement to acquire a biopharmaceutical company that focuses on the development of pain treatments.

NEW YORK — Pfizer has entered a definitive agreement to acquire a biopharmaceutical company that focuses on the development of pain treatments.

Pfizer, which currently owns a near 11% stake in Icagen, will acquire the company's remaining 8.3 million shares. The aggregate transaction value, which includes the value of the shares currently owned by Pfizer, is about $56 million.

The two companies entered a discovery, development and commercialization collaboration in 2007, which sought to create potential treatments for pain and related disorders.

April 27, 2011

A biopharmaceutical company has appointed a new CFO.

CAMBRIDGE, Mass. — A biopharmaceutical company has appointed a new CFO.

Aegerion Pharmaceuticals named Mark Fitzpatrick as the company's new CFO. Fitzpatrick joins the company, which is focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, from Proteon Therapeutics, where he served as VP, CFO and assistant secretary.

March 30, 2011

A biopharmaceutical company that specializes in diabetes treatments has appointed a new board chairman.

DANBURY, Conn. — A biopharmaceutical company that specializes in diabetes treatments has appointed a new board chairman.

Biodel said that effective immediately, Brian Pereira, who has served on the drug maker's board since 2007, will become chairman. Current chairman Charles Sanders, who served as chairman since March 2010 after joining the board in August 2006, will continue to serve as a board member, Biodel said.

March 9, 2011

Eli Lilly leader John Lechleiter has become something of an evangelist for medical innovation lately. On Wednesday, the Lilly chairman, president and CEO spoke to the U.S./Japan Business Council in Tokyo to call for changes and policies in the biopharmaceutical industry that encourage innovation, or “reinventing invention,” as he called it.

TOKYO — Eli Lilly leader John Lechleiter has become something of an evangelist for medical innovation lately.

On Wednesday, the Lilly chairman, president and CEO spoke to the U.S./Japan Business Council in Tokyo to call for changes and policies in the biopharmaceutical industry that encourage innovation, or “reinventing invention,” as he called it.

February 2, 2011

A new report developed by the Pharmaceutical Research and Manufacturers of America revealed that nearly 300 heart disease and stroke medicines are in development.

WASHINGTON — A new report developed by the Pharmaceutical Research and Manufacturers of America revealed that nearly 300 heart disease and stroke medicines are in development.

PhRMA said that while 299 medicines are in development by the nation's biopharmaceutical companies, there is a growing need for such drugs; African-Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

January 25, 2011

John Johnson is bidding Eli Lilly adieu.

INDIANAPOLIS — John Johnson is bidding Eli Lilly adieu.

Johnson, who served as SVP and president of the drug maker's oncology business — whose portfolio includes Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride) — resigned, effective Jan. 28. Johnson is taking on the chief executive role at specialty biopharmaceutical company Savient, effective Jan. 31. Savient is best known for its chronic gout treatment Krystexxa (pegloticase), which received regulatory approval in September 2010.

December 21, 2010

Abbott has made a pact with a biopharmaceutical company to develop new cancer treatments by making small-molecule inhibitors.

ABBOTT PARK, Ill. — Abbott has made a pact with a biopharmaceutical company to develop new cancer treatments by making small-molecule inhibitors.

Under the terms of the agreement, Abbott will provide EpiTherapeutics with an up-front payment and will receive funding of research activities conducted at EpiTherapeutics. The biopharmaceutical company also is eligible, under certain conditions, to receive milestone payments as well as potential royalties on future revenues.

December 21, 2010

A biopharmaceutical company exclusively will develop and commercialize oral formulations of a drug maker's insulins.

PRINCETON, N.J. — A biopharmaceutical company exclusively will develop and commercialize oral formulations of a drug maker's insulins.

Emisphere will be paid $57.5 million in potential product development and sales milestone payments by Novo Nordisk — of which $5 million dollars will be payable upon signing — as well as royalties on sales. Further financial details of the agreement were not disclosed.